It’s a pleasure to announce the multidisciplinary, think-tank style symposium at Stanford University on April 13th & 14th 2023 on the topic of Drug Induced Pulmonary Hypertension. The symposium will be hybrid (in-person and live streaming) and is CME accredited.

Despite the progress in the diagnosis, clinical care, and treatment of PH patients, unique etiological factors are still being discovered. Iatrogenic forms of PH are arguably one of the leading but under-appreciated causes of the disease in the modern era. The rationale for this symposium is to leverage subject-matter expertise from international academic centers and Stanford University, engage the broader academic communities, global organizations (World Health Organization, United States Food and Drug Administration, European Medicines Agency), and stake-holders (patients, industry partners, etc) to develop a deeper understanding of “drug induced pulmonary hypertension” and establish pharmacovigilance protocols for monitoring drug safety and rapid identification of PH in at-risk populations.

Learn more about the current agenda, symposium information, and you can also register at https://med.stanford.edu/phsymposium.html